Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma

Eugster, Philippe J.; Maurer, Jonathan; Vocat, Céline; Abid, Karim; Matter, Maurice; Wuerzner, Grégoire; Trepp, Roman; Fischli, Stefan; Henzen, Christoph; Kolb, Werner; Bilz, Stefan; Sigrist, Sarah; Beuschlein, Felix; Nölting, Svenja; Reul, Astrid; Schütze, Ina; Hubers, Scott A.; Brown, Nancy J.; Grouzmann, Eric

doi:10.1016/j.cca.2022.07.018

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were taken before the CPT, at 30 s and 2 min of the CPT, and 2 min after the end of the CPT. Norepinephrine (NE), epinephrine (E) and neuropeptide Y (NPY) 1–36 and its metabolites, were determined using a liquid chromatography tandem mass spectrometry method as reported previously [ 13 , 14 ]. Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were determined by a radioimmunoassay kit for the quantitative determination of Angiotensin I in human plasma (REN-CT2, Cisbio Bioassays, Codolet, France) and by a commercial RIA kit (Aldo-Riact, CIS Bio International, Yvette, Cedex, Saclay, France) respectively.…”

Section: Methodsmentioning

confidence: 99%

Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow reserve in hypertensive patients

Damianaki

Hendriks-Balk

Brito

et al. 2023

Nephrology Dialysis Transplantation

Self Cite

View full text Add to dashboard Cite

Background Microvascular structural alteration and dysfunction is a hallmark of arterial hypertension. So far, the visualization and the quantification of renal microcirculation in humans has been hampered by the lack of non-nephrotoxic and non-invasive radiologic techniques. Contrast-Enhanced ultrasonography (CEUS) is an alluring method to investigate renal microcirculation and has not been investigated in this setting. We aimed to compare renal microcirculation in normotensives (NT) and hypertensive (HT) participants using CEUS at rest and during a sympathetic stress test. Methods We measured the renal perfusion index (PI, primary outcome), the renal resistive index (RRI), beat-to-beat systemic hemodynamics and plasma catecholamines before and during a 2-minute cold pressor test (CPT) in NT and HT participants. Linear mixed model analysis was used to compare the effect of the CPT on the variables of interest. Results 73 participants (32 HT) with normal kidney function were included. HT participants had a lower baseline PI compared to NT participants [1476(959–2155) arbitrary unit (a.u.) vs 2062(1438–3318) a.u., p < 0.001]. The CPT increased blood pressure, heart rate and catecholamines in all participants. The increase in PI observed in NT during the CPT was blunted in HT (+504(117–920) a.u. vs + 1159(678–2352) a.u in NT, interaction p = 0.013). Age, sex and body mass index did not modify these results. Conclusions HT patients had a lower basal renal cortical perfusion. During the cold pressor test, HT participants had a smaller increase in the PI, suggesting that renal cortical flow reserve is impaired.

show abstract

Section: Methodsmentioning

confidence: 99%

Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow reserve in hypertensive patients

Damianaki

Hendriks-Balk

Brito

et al. 2023

Nephrology Dialysis Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result, these tumors release NPY into the vascular system. It has been suggested that the plasma NPY level could be used as an early diagnostic marker for pheochromocytomas and paragangliomas in patients who received treatments that interfere with catecholamine reuptake or suffer from severe kidney impairment [ 224 ]. Lower NPY levels were observed in pheochromocytomas from von Hippel-Lindau patients (noradrenergic phenotype) when compared with pheochromocytomas from multiple endocrine neoplasia type 2 patients (adrenergic phenotype) [ 225 ].…”

Section: Involvement Of Neuropeptide Y Peptide Yy and Pancreatic Poly...mentioning

confidence: 99%

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

Sánchez

Rodríguez

Coveñas

2023

IJMS

View full text Add to dashboard Cite

Currently available data on the involvement of neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) and their receptors (YRs) in cancer are updated. The structure and dynamics of YRs and their intracellular signaling pathways are also studied. The roles played by these peptides in 22 different cancer types are reviewed (e.g., breast cancer, colorectal cancer, Ewing sarcoma, liver cancer, melanoma, neuroblastoma, pancreatic cancer, pheochromocytoma, and prostate cancer). YRs could be used as cancer diagnostic markers and therapeutic targets. A high Y1R expression has been correlated with lymph node metastasis, advanced stages, and perineural invasion; an increased Y5R expression with survival and tumor growth; and a high serum NPY level with relapse, metastasis, and poor survival. YRs mediate tumor cell proliferation, migration, invasion, metastasis, and angiogenesis; YR antagonists block the previous actions and promote the death of cancer cells. NPY favors tumor cell growth, migration, and metastasis and promotes angiogenesis in some tumors (e.g., breast cancer, colorectal cancer, neuroblastoma, pancreatic cancer), whereas in others it exerts an antitumor effect (e.g., cholangiocarcinoma, Ewing sarcoma, liver cancer). PYY or its fragments block tumor cell growth, migration, and invasion in breast, colorectal, esophageal, liver, pancreatic, and prostate cancer. Current data show the peptidergic system’s high potential for cancer diagnosis, treatment, and support using Y2R/Y5R antagonists and NPY or PYY agonists as promising antitumor therapeutic strategies. Some important research lines to be developed in the future will also be suggested.

show abstract

“…NPY is a neurotransmitter whose high plasma levels are found in several cancers, including pheochromocytoma, ganglioma, and neuroblastoma, in which it can be used as a marker [59,78]. Despite the measurement of catecholamines displaying a higher sensitivity in pheochromocytoma and paraganglioma, NPY may be a viable alternative in patients suffering from kidney impairment or under treatments that interfere with catecholamine reuptake [79]. However, its clinical use is limited due to the low amount of information available, thus requiring further in-depth studies [79].…”

Section: Other Biomarkersmentioning

confidence: 99%

An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide

Bevere,

Masetto,

Carazzolo

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are a heterogeneous group of diseases that are characterized by different behavior and clinical manifestations. The diagnosis and management of this group of tumors are challenging due to tumor complexity and lack of precise and widely validated biomarkers. Indeed, the current circulating mono-analyte biomarkers (such as chromogranin A) are ineffective in describing such complex tumors due to their poor sensitivity and specificity. In contrast, multi-analytical circulating biomarkers (including NETest) are emerging as more effective tools to determine the real-time profile of the disease, both in terms of accurate diagnosis and effective treatment. In this review, we will analyze the capabilities and limitations of different circulating biomarkers focusing on three relevant questions: (1) accurate and early diagnosis; (2) monitoring of disease progression and response to therapy; and (3) detection of early relapse.

show abstract

Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma

Cited by 5 publications

References 29 publications

Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow reserve in hypertensive patients

Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow reserve in hypertensive patients

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide

Contact Info

Product

Resources

About